Intrahepatic Cholangiocarcinoma
📧 Sign up to get email alerts when something new happens for Intrahepatic Cholangiocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery [Phase 2]
A Phase 2 clinical trial is exploring delivering chemotherapy directly into the liver with a pump for intrahepatic bile duct cancer (intrahe…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) [Phase 2]
Phase 2 clinical trial evaluating hepatic arterial infusion with floxuridine and dexamethasone in combination with systemic gemcitabine and …
-
CLINICAL_TRIALS trial_result · 2025-03-18Clinical Trial Update: Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Expanded Access for ABC294640 (Yeliva) in advanced cholangiocarcinoma has been closed and is no longer available.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This clinical trial update describes liver transplantation for patients with unresectable intrahepatic cholangiocarcinoma who have achieved …
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors [Phase 2]
Phase 2 trial evaluating neoadjuvant hepatic arterial infusion chemotherapy with GEMOX plus adebrelimab and lenvatinib for resectable intrah…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer [Phase 2]
Phase II study evaluating GemOX hepatic arterial infusion combined with lenvatinib and toripalimab for advanced unresectable intrahepatic ch…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
This Phase 2 trial update describes evaluating a combination of transarterial chemoembolization (TACE) and tislelizumab in patients with adv…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating cryoablation in combination with an anti-PD-1 antibody for advanced intrahepatic cholangiocarcinoma is currently re…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer [Phase 2]
This clinical trial update reports a Phase 2 study evaluating the combination of lenvatinib and sintilimab for advanced liver cancer (intrah…
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 trial evaluating cryoablation in combination with sintilimab and lenvatinib for advanced intrahepatic cholangiocarcinoma has compl…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC [Phase 2]
Phase 2 study of DEB-TACE combined with Surufatinib and Camrelizumab for inoperable or metastatic intrahepatic cholangiocarcinoma has comple…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence [Phase 2]
Phase 2 clinical trial evaluating GOT as a neoadjuvant regimen for patients with resectable intrahepatic cholangiocarcinoma at high risk of …
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 trial evaluating two regimens—toripalimab with lenvatinib, or gemcitabine/oxaliplatin with lenvatinib—in advanced intrahepatic cho…
-
CLINICAL_TRIALS withdrawal · 2025-02-05Clinical Trial Update: Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies [Phase 4]
A Phase 4 trial assessing the Surefire Infusion Device in regional intra-arterial therapy for primary liver malignancies has been withdrawn.…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of tislelizumab and S-1 for patients with postoperative recurrent high-risk intrahepa…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) [NA]
The LIVELONG trial from University of California, Davis is an ongoing study evaluating locally ablative therapy for oligoprogressive gastroi…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery [Phase 2]
Phase 2 trial evaluating SHR-1210 (tislelizumab) plus capecitabine for postoperative intrahepatic cholangiocarcinoma is active but not recru…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 clinical study of VG161 for advanced intrahepatic cholangiocarcinoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: Liver Transplantation for Early Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating liver transplantation for early intrahepatic cholangiocarcinoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating toripalimab in combination with gemcitabine and cisplatin as preoperative neoadjuvant therapy for resectable intrah…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma
A completed clinical trial update evaluating a machine-learning model to predict lymph node metastasis in intrahepatic cholangiocarcinoma.
-
CLINICAL_TRIALS research · 2024-11-21Clinical Trial Update: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 clinical trial update about using hepatic arterial infusion chemotherapy (HAIC) with subsequent transarterial embolization (TAE) i…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma [NA]
A clinical trial evaluating gemcitabine, cisplatin, and Yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma has be…
-
CLINICAL_TRIALS withdrawal · 2024-11-12Clinical Trial Update: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 neoadjuvant trial of tremelimumab and durvalumab with gemcitabine/cisplatin for intrahepatic cholangiocarcinoma has been withdrawn.
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
A Phase 2 clinical trial is evaluating a combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and pucotenlimab as conve…